Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Back-to-Germline (B2G) Procedure for Antibody Devolution.

Schrade A, Bujotzek A, Spick C, Wagner M, Goerl J, Wezler X, Georges G, Kontermann RE, Brinkmann U.

Antibodies (Basel). 2019 Aug 26;8(3). pii: E45. doi: 10.3390/antib8030045.

2.

TNFR2 promotes Treg-mediated recovery from neuropathic pain across sexes.

Fischer R, Sendetski M, Del Rivero T, Martinez GF, Bracchi-Ricard V, Swanson KA, Pruzinsky EK, Delguercio N, Rosalino MJ, Padutsch T, Kontermann RE, Pfizenmaier K, Bethea JR.

Proc Natl Acad Sci U S A. 2019 Aug 20;116(34):17045-17050. doi: 10.1073/pnas.1902091116. Epub 2019 Aug 7.

3.

Exogenous activation of tumor necrosis factor receptor 2 promotes recovery from sensory and motor disease in a model of multiple sclerosis.

Fischer R, Padutsch T, Bracchi-Ricard V, Murphy KL, Martinez GF, Delguercio N, Elmer N, Sendetski M, Diem R, Eisel ULM, Smeyne RJ, Kontermann RE, Pfizenmaier K, Bethea JR.

Brain Behav Immun. 2019 Oct;81:247-259. doi: 10.1016/j.bbi.2019.06.021. Epub 2019 Jun 17.

PMID:
31220564
4.

IL15-Based Trifunctional Antibody-Fusion Proteins with Costimulatory TNF-Superfamily Ligands in the Single-Chain Format for Cancer Immunotherapy.

Beha N, Harder M, Ring S, Kontermann RE, Müller D.

Mol Cancer Ther. 2019 Jul;18(7):1278-1288. doi: 10.1158/1535-7163.MCT-18-1204. Epub 2019 Apr 30.

PMID:
31040163
5.

Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules.

Seifert O, Rau A, Beha N, Richter F, Kontermann RE.

MAbs. 2019 Jul;11(5):919-929. doi: 10.1080/19420862.2019.1603024. Epub 2019 May 3.

PMID:
30951400
6.

Continuous infusion of an agonist of the tumor necrosis factor receptor 2 in the spinal cord improves recovery after traumatic contusive injury.

Gerald MJ, Bracchi-Ricard V, Ricard J, Fischer R, Nandakumar B, Blumenthal GH, Williams R, Kontermann RE, Pfizenmaier K, Moxon KA, Bethea JR.

CNS Neurosci Ther. 2019 Aug;25(8):884-893. doi: 10.1111/cns.13125. Epub 2019 Apr 2.

7.

Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc.

Richter F, Seifert O, Herrmann A, Pfizenmaier K, Kontermann RE.

MAbs. 2019 May/Jun;11(4):653-665. doi: 10.1080/19420862.2019.1596512. Epub 2019 Mar 31.

PMID:
30929560
8.

Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma.

Del Mistro G, Lucarelli P, Müller I, De Landtsheer S, Zinoveva A, Hutt M, Siegemund M, Kontermann RE, Beissert S, Sauter T, Kulms D.

NPJ Syst Biol Appl. 2018 Nov 5;4:39. doi: 10.1038/s41540-018-0075-y. eCollection 2018.

9.

Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism.

Lincoln FA, Imig D, Boccellato C, Juric V, Noonan J, Kontermann RE, Allgöwer F, Murphy BM, Rehm M.

Cell Death Dis. 2018 Nov 1;9(11):1112. doi: 10.1038/s41419-018-1160-2.

10.

Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity.

Richter F, Zettlitz KA, Seifert O, Herrmann A, Scheurich P, Pfizenmaier K, Kontermann RE.

MAbs. 2019 Jan;11(1):166-177. doi: 10.1080/19420862.2018.1524664. Epub 2018 Oct 2.

11.

Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans.

Fellermeier-Kopf S, Gieseke F, Sahin U, Müller D, Pfizenmaier K, Kontermann RE.

Oncoimmunology. 2018 Aug 1;7(9):e1471442. doi: 10.1080/2162402X.2018.1471442. eCollection 2018.

12.

Dataset on the role of endoglin expression on melanin production in murine melanoma and on the influence of melanin on optical imaging.

Tansi FL, Rüger R, Kollmeier AM, Rabenhold M, Steiniger F, Kontermann RE, Teichgraeber UK, Fahr A, Hilger I.

Data Brief. 2018 Aug 31;20:1048-1052. doi: 10.1016/j.dib.2018.08.110. eCollection 2018 Oct.

13.

Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.

Satta A, Mezzanzanica D, Caroli F, Frigerio B, Di Nicola M, Kontermann RE, Iacovelli F, Desideri A, Anichini A, Canevari S, Gianni AM, Figini M.

MAbs. 2018 Oct;10(7):1084-1097. doi: 10.1080/19420862.2018.1494105. Epub 2018 Aug 6.

14.

IgG-single-chain TRAIL fusion proteins for tumour therapy.

Siegemund M, Schneider F, Hutt M, Seifert O, Müller I, Kulms D, Pfizenmaier K, Kontermann RE.

Sci Rep. 2018 May 17;8(1):7808. doi: 10.1038/s41598-018-24450-8.

15.

Endoglin based in vivo near-infrared fluorescence imaging of tumor models in mice using activatable liposomes.

Tansi FL, Rüger R, Kollmeier AM, Rabenhold M, Steiniger F, Kontermann RE, Teichgraeber UK, Fahr A, Hilger I.

Biochim Biophys Acta Gen Subj. 2018 Jun;1862(6):1389-1400. doi: 10.1016/j.bbagen.2018.03.012. Epub 2018 Mar 13.

16.

Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells.

Hutt M, Fellermeier-Kopf S, Seifert O, Schmitt LC, Pfizenmaier K, Kontermann RE.

Oncotarget. 2018 Jan 31;9(13):11322-11335. doi: 10.18632/oncotarget.24379. eCollection 2018 Feb 16.

17.

Transcytosis of payloads that are non-covalently complexed to bispecific antibodies across the hCMEC/D3 blood-brain barrier model.

Schmid D, Buntz A, Hanh Phan TN, Mayer K, Hoffmann E, Thorey I, Niewöhner J, Vasters K, Sircar R, Mundigl O, Kontermann RE, Brinkmann U.

Biol Chem. 2018 Jun 27;399(7):711-721. doi: 10.1515/hsz-2017-0311.

PMID:
29466231
18.

Selective Activation of Tumor Necrosis Factor Receptor II Induces Antiinflammatory Responses and Alleviates Experimental Arthritis.

Fischer R, Proske M, Duffey M, Stangl H, Martinez GF, Peters N, Kraske A, Straub RH, Bethea JR, Kontermann RE, Pfizenmaier K.

Arthritis Rheumatol. 2018 May;70(5):722-735. doi: 10.1002/art.40413. Epub 2018 Mar 11.

19.

Corrigendum to "Bispecific antibodies" [Drug Discov. Today 20 (July (7)) (2015) 838-847].

Kontermann RE, Brinkmann U.

Drug Discov Today. 2019 Jul;24(7):1422. doi: 10.1016/j.drudis.2017.12.004. Epub 2018 Jan 5. No abstract available.

PMID:
29309739
20.

Superior Properties of Fc-comprising scTRAIL Fusion Proteins.

Hutt M, Marquardt L, Seifert O, Siegemund M, Müller I, Kulms D, Pfizenmaier K, Kontermann RE.

Mol Cancer Ther. 2017 Dec;16(12):2792-2802. doi: 10.1158/1535-7163.MCT-17-0551. Epub 2017 Sep 13.

21.

Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2.

Fischer R, Marsal J, Guttà C, Eisler SA, Peters N, Bethea JR, Pfizenmaier K, Kontermann RE.

Sci Rep. 2017 Jul 26;7(1):6607. doi: 10.1038/s41598-017-06993-4.

22.

Antitumor Activity of a Mesenchymal Stem Cell Line Stably Secreting a Tumor-Targeted TNF-Related Apoptosis-Inducing Ligand Fusion Protein.

Marini I, Siegemund M, Hutt M, Kontermann RE, Pfizenmaier K.

Front Immunol. 2017 May 11;8:536. doi: 10.3389/fimmu.2017.00536. eCollection 2017.

23.

Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV.

Schmitt LC, Rau A, Seifert O, Honer J, Hutt M, Schmid S, Zantow J, Hust M, Dübel S, Olayioye MA, Kontermann RE.

MAbs. 2017 Jul;9(5):831-843. doi: 10.1080/19420862.2017.1319023. Epub 2017 Apr 19.

24.

Activatable bispecific liposomes bearing fibroblast activation protein directed single chain fragment/Trastuzumab deliver encapsulated cargo into the nuclei of tumor cells and the tumor microenvironment simultaneously.

Tansi FL, Rüger R, Böhm C, Steiniger F, Kontermann RE, Teichgraeber UK, Fahr A, Hilger I.

Acta Biomater. 2017 May;54:281-293. doi: 10.1016/j.actbio.2017.03.033. Epub 2017 Mar 24.

25.

A fast and effective determination of the biodistribution and subcellular localization of fluorescent immunoliposomes in freshly excised animal organs.

Tansi FL, Rüger R, Kollmeier AM, Böhm C, Kontermann RE, Teichgraeber UK, Fahr A, Hilger I.

BMC Biotechnol. 2017 Jan 18;17(1):8. doi: 10.1186/s12896-017-0327-8.

26.

The making of bispecific antibodies.

Brinkmann U, Kontermann RE.

MAbs. 2017 Feb/Mar;9(2):182-212. doi: 10.1080/19420862.2016.1268307. Review.

27.

Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format.

Fellermeier S, Beha N, Meyer JE, Ring S, Bader S, Kontermann RE, Müller D.

Oncoimmunology. 2016 Sep 27;5(11):e1238540. doi: 10.1080/2162402X.2016.1238540. eCollection 2016.

28.

Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration.

Dong Y, Fischer R, Naudé PJ, Maier O, Nyakas C, Duffey M, Van der Zee EA, Dekens D, Douwenga W, Herrmann A, Guenzi E, Kontermann RE, Pfizenmaier K, Eisel UL.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12304-12309. Epub 2016 Oct 10.

29.

Dataset on FAP-induced emergence of spontaneous metastases and on the preparation of activatable FAP-targeting immunoliposomes to detect the metastases.

Tansi FL, Rüger R, Böhm C, Kontermann RE, Teichgraeber UK, Fahr A, Hilger I.

Data Brief. 2016 Sep 3;9:143-8. doi: 10.1016/j.dib.2016.08.058. eCollection 2016 Dec.

30.

An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.

Siegemund M, Seifert O, Zarani M, Džinić T, De Leo V, Göttsch D, Münkel S, Hutt M, Pfizenmaier K, Kontermann RE.

MAbs. 2016 Jul;8(5):879-91. doi: 10.1080/19420862.2016.1172163. Epub 2016 Apr 11.

31.

Half-life extended biotherapeutics.

Kontermann RE.

Expert Opin Biol Ther. 2016 Jul;16(7):903-15. doi: 10.1517/14712598.2016.1165661. Epub 2016 Apr 18. Review. Erratum in: Expert Opin Biol Ther. 2016 Sep;16(9):1179.

PMID:
26967759
32.

Potential of activatable FAP-targeting immunoliposomes in intraoperative imaging of spontaneous metastases.

Tansi FL, Rüger R, Böhm C, Kontermann RE, Teichgraeber UK, Fahr A, Hilger I.

Biomaterials. 2016 May;88:70-82. doi: 10.1016/j.biomaterials.2016.02.028. Epub 2016 Feb 23.

33.

Pharmacokinetic properties of IgG and various Fc fusion proteins in mice.

Unverdorben F, Richter F, Hutt M, Seifert O, Malinge P, Fischer N, Kontermann RE.

MAbs. 2016;8(1):120-8. doi: 10.1080/19420862.2015.1113360.

34.

A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties.

Unverdorben F, Hutt M, Seifert O, Kontermann RE.

PLoS One. 2015 Oct 2;10(10):e0139838. doi: 10.1371/journal.pone.0139838. eCollection 2015.

35.

Immunoliposomes for Targeted Delivery of an Antifibrotic Drug.

Schuster L, Seifert O, Vollmer S, Kontermann RE, Schlosshauer B, Hartmann H.

Mol Pharm. 2015 Sep 8;12(9):3146-57. doi: 10.1021/acs.molpharmaceut.5b00012. Epub 2015 Jul 28.

PMID:
26181293
36.

Bispecific antibodies.

Kontermann RE, Brinkmann U.

Drug Discov Today. 2015 Jul;20(7):838-47. doi: 10.1016/j.drudis.2015.02.008. Epub 2015 Feb 26. Review. Erratum in: Drug Discov Today. 2018 Jan 5;:.

37.

Tailoring the stealth properties of biocompatible polysaccharide nanocontainers.

Kang B, Okwieka P, Schöttler S, Seifert O, Kontermann RE, Pfizenmaier K, Musyanovych A, Meyer R, Diken M, Sahin U, Mailänder V, Wurm FR, Landfester K.

Biomaterials. 2015 May;49:125-34. doi: 10.1016/j.biomaterials.2015.01.042. Epub 2015 Feb 16.

PMID:
25725561
38.

Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously.

Rabenhold M, Steiniger F, Fahr A, Kontermann RE, Rüger R.

J Control Release. 2015 Mar 10;201:56-67. doi: 10.1016/j.jconrel.2015.01.022. Epub 2015 Jan 21.

PMID:
25617725
39.

Tumor-antigen-binding bispecific antibodies for cancer treatment.

Weidle UH, Kontermann RE, Brinkmann U.

Semin Oncol. 2014 Oct;41(5):653-60. doi: 10.1053/j.seminoncol.2014.08.004. Epub 2014 Aug 12. Review.

40.

An EGF receptor targeting Ranpirnase-diabody fusion protein mediates potent antitumour activity in vitro and in vivo.

Kiesgen S, Arndt MAE, Körber C, Arnold U, Weber T, Halama N, Keller A, Bötticher B, Schlegelmilch A, Liebers N, Cremer M, Herold-Mende C, Dyckhoff G, Federspil PA, Jensen AD, Jäger D, Kontermann RE, Mier W, Krauss J.

Cancer Lett. 2015 Feb 1;357(1):364-373. doi: 10.1016/j.canlet.2014.11.054. Epub 2014 Nov 27.

PMID:
25434798
41.

Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.

Fernández-Ulibarri I, Hammer K, Arndt MA, Kaufmann JK, Dorer D, Engelhardt S, Kontermann RE, Hess J, Allgayer H, Krauss J, Nettelbeck DM.

Int J Cancer. 2015 May 1;136(9):2228-40. doi: 10.1002/ijc.29258. Epub 2014 Nov 12.

42.

A fusogenic dengue virus-derived peptide enhances antitumor efficacy of an antibody-ribonuclease fusion protein targeting the EGF receptor.

Kiesgen S, Liebers N, Cremer M, Arnold U, Weber T, Keller A, Herold-Mende C, Dyckhoff G, Jäger D, Kontermann RE, Arndt MA, Krauss J.

Protein Eng Des Sel. 2014 Oct;27(10):331-7. doi: 10.1093/protein/gzu040.

PMID:
25301960
43.

In vivo near-infrared fluorescence imaging of FAP-expressing tumors with activatable FAP-targeted, single-chain Fv-immunoliposomes.

Rüger R, Tansi FL, Rabenhold M, Steiniger F, Kontermann RE, Fahr A, Hilger I.

J Control Release. 2014 Jul 28;186:1-10. doi: 10.1016/j.jconrel.2014.04.050. Epub 2014 May 5.

PMID:
24810115
44.

Immuno-LipoTRAIL: Targeted delivery of TRAIL-functionalized liposomal nanoparticles.

Seifert O, Pollak N, Nusser A, Steiniger F, Rüger R, Pfizenmaier K, Kontermann RE.

Bioconjug Chem. 2014 May 21;25(5):879-87. doi: 10.1021/bc400517j. Epub 2014 May 7.

PMID:
24766622
45.

Expression and purification of recombinant antibody formats and antibody fusion proteins.

Siegemund M, Richter F, Seifert O, Unverdorben F, Kontermann RE.

Methods Mol Biol. 2014;1131:273-95. doi: 10.1007/978-1-62703-992-5_18.

PMID:
24515473
46.

Generation of “LYmph Node Derived Antibody Libraries” (LYNDAL) for selecting fully human antibody fragments with therapeutic potential.

Diebolder P, Keller A, Haase S, Schlegelmilch A, Kiefer JD, Karimi T, Weber T, Moldenhauer G, Kehm R, Eis-Hübinger AM, Jäger D, Federspil PA, Herold-Mende C, Dyckhoff G, Kontermann RE, Arndt MA, Krauss J.

MAbs. 2014 Jan-Feb;6(1):130-42.

47.

Combining antibody-directed presentation of IL-15 and 4-1BBL in a trifunctional fusion protein for cancer immunotherapy.

Kermer V, Hornig N, Harder M, Bondarieva A, Kontermann RE, Müller D.

Mol Cancer Ther. 2014 Jan;13(1):112-21. doi: 10.1158/1535-7163.MCT-13-0282. Epub 2013 Nov 6.

48.

Tetravalent antibody-scTRAIL fusion proteins with improved properties.

Seifert O, Plappert A, Fellermeier S, Siegemund M, Pfizenmaier K, Kontermann RE.

Mol Cancer Ther. 2014 Jan;13(1):101-11. doi: 10.1158/1535-7163.MCT-13-0396. Epub 2013 Oct 3.

49.

An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action.

Berger V, Richter F, Zettlitz K, Unverdorben F, Scheurich P, Herrmann A, Pfizenmaier K, Kontermann RE.

Protein Eng Des Sel. 2013 Oct;26(10):581-7. doi: 10.1093/protein/gzt044. Epub 2013 Sep 4.

PMID:
24006371
50.

Antagonistic TNF receptor one-specific antibody (ATROSAB): receptor binding and in vitro bioactivity.

Richter F, Liebig T, Guenzi E, Herrmann A, Scheurich P, Pfizenmaier K, Kontermann RE.

PLoS One. 2013 Aug 19;8(8):e72156. doi: 10.1371/journal.pone.0072156. eCollection 2013.

Supplemental Content

Loading ...
Support Center